Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

The administration of Donald Trump has reportedly terminated funding for several HIV vaccine research programs.

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...

U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

The global response to HIV has reached a crucial juncture. Groundbreaking scientific advances, including the development of ...

Everyone who wants a new HIV shot* should be given it, according to Yvette Raphael, who chaired the Global Community Advisory Group for the large-scale clinical trials of the long-acting HIV treatment ...

In this randomized controlled trial, among men and gender-diverse persons who have sex with men, it was found that ...